Drugs / 68Ga-NOTA-exendin-4
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02560376 | Feb 2014 → Dec 2016 | islet cell adenomatosis, pancreatic insulinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04979611 | Aug 2020 → Aug 2025 | pancreatic insulinoma | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NOTA-exendin-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04979611 ↗ |
| Modality | Diagnostic / imaging agent | “positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-exendin-4” NCT02560376 ↗ |
| Route | Intravenous | “A single dose of 55.5-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously.” NCT02560376 ↗ |
| Target | GLP1R | “68Ga-NOTA-exendin-4 is an optimal probe targeting GLP-1R.” NCT02560376 ↗ |